key: cord-0701309-n6ztj5sm authors: Ghasemian, Roya; Shamshirian, Amir; Heydari, Keyvan; Malekan, Mohammad; Alizadeh‐Navaei, Reza; Ebrahimzadeh, Mohammad Ali; Ebrahimi Warkiani, Majid; Jafarpour, Hamed; Razavi Bazaz, Sajad; Rezaei Shahmirzadi, Arash; Khodabandeh, Mehrdad; Seyfari, Benyamin; Motamedzadeh, Alireza; Dadgostar, Ehsan; Aalinezhad, Marzieh; Sedaghat, Meghdad; Razzaghi, Nazanin; Zarandi, Bahman; Asadi, Anahita; Yaghoubi Naei, Vahid; Beheshti, Reza; Hessami, Amirhossein; Azizi, Soheil; Mohseni, Ali Reza; Shamshirian, Danial title: The role of vitamin D in the age of COVID‐19: A systematic review and meta‐analysis date: 2021-08-06 journal: Int J Clin Pract DOI: 10.1111/ijcp.14675 sha: b2b91e0ee6857cbac6961920bfda73a4734611a7 doc_id: 701309 cord_uid: n6ztj5sm BACKGROUND: Evidence recommends that vitamin D might be a crucial supportive agent for the immune system, mainly in cytokine response regulation against COVID‐19. Hence, we carried out a systematic review and meta‐analysis in order to maximise the use of everything that exists about the role of vitamin D in the COVID‐19. METHODS: A systematic search was performed in PubMed, Scopus, Embase and Web of Science up to December 18, 2020. Studies focused on the role of vitamin D in confirmed COVID‐19 patients were entered into the systematic review. RESULTS: Twenty‐three studies containing 11 901 participants entered into the meta‐analysis. The meta‐analysis indicated that 41% of COVID‐19 patients were suffering from vitamin D deficiency (95% CI, 29%‐55%), and in 42% of patients, levels of vitamin D were insufficient (95% CI, 24%‐63%). The serum 25‐hydroxyvitamin D concentration was 20.3 ng/mL among all COVID‐19 patients (95% CI, 12.1‐19.8). The odds of getting infected with SARS‐CoV‐2 are 3.3 times higher among individuals with vitamin D deficiency (95% CI, 2.5‐4.3). The chance of developing severe COVID‐19 is about five times higher in patients with vitamin D deficiency (OR: 5.1, 95% CI, 2.6‐10.3). There is no significant association between vitamin D status and higher mortality rates (OR: 1.6, 95% CI, 0.5‐4.4). CONCLUSION: This study found that most of the COVID‐19 patients were suffering from vitamin D deficiency/insufficiency. Also, there is about three times higher chance of getting infected with SARS‐CoV‐2 among vitamin‐D‐deficient individuals and about five times higher probability of developing the severe disease in vitamin‐D‐deficient patients. Vitamin D deficiency showed no significant association with mortality rates in this population. After months of medical communities' efforts, one of the hottest topics is still the role of Vitamin D in the prevention or treatment of COVID-19. Several functions, such as modulating the adaptive immune system and cell-mediated immunity, as well as an increase of antioxidative-related genes expression, have been proven for Vitamin D as an adjuvant in the prevention and treatment of acute respiratory infections. [2] [3] [4] According to available investigations, it seems that such functions lead to cytokine storm suppression and avoid Acute Respiratory Distress Syndrome (ARDS), which has been studied on other pandemics and infectious diseases in recent years. [4] [5] [6] [7] To the best of our knowledge, unfortunately, after several months, there is no adequate high-quality data on different treatment regimens, which raise questions about gaps in scientific works. On this occasion, when there is an essential need for controlled randomised trials, it is surprising to see only observational studies without a control group or non-randomised con- The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was considered for the study plan. A systematic search through databases of PubMed, Scopus, Embase and Web of Science was done up to December 18, 2020. Moreover, Methods:A systematic search was performed in PubMed, Scopus, Embase and Web of Science up to December 18, 2020 . Studies focused on the role of vitamin D in confirmed COVID-19 patients were entered into the systematic review. Conclusion:This study found that most of the COVID-19 patients were suffering from vitamin D deficiency/insufficiency. Also, there is about three times higher chance of getting infected with SARS-CoV-2 among vitamin-D-deficient individuals and about five times higher probability of developing the severe disease in vitamin-D-deficient patients. Vitamin D deficiency showed no significant association with mortality rates in this population. Following database search, paper screening, data extraction and quality assessment were done based on inclusion and exclusion criteria by independent researchers. Our study demonstrated a significant association between vitamin D deficiency/insufficiency and SARS-CoV-2 infection, which can be helpful to consider in the clinical setting. to obtain more data, we considered grey literature and references of eligible papers. The search strategy included all MeSH terms and free keywords found for COVID-19, SARS-CoV-2 and Vitamin D (Table S1 ). There was no time/location/language limitation in this search. Four researchers have screened and selected the papers independently, and the supervisor solved the disagreements. Studies met the following criteria included in the meta-analysis: 1) comparative or non-comparative studies with retrospective or prospective nature; and 2) studies reported the role of vitamin D in confirmed COVID-19 patients. Studies were excluded if they were: 1) in vitro studies, experimental studies, reviews, 2) duplicate publications. 9 and Jadad scale 10 for randomised clinical trials were used to value the studies concerning various aspects of the methodology and study process. In this case, according to most of the studies, vitamin D cut-off points were considered as follows: • Vitamin D sufficiency: 25(OH)D concentration greater than 30 ng/mL. Meta-analysis was performed using Comprehensive Meta-Analysis Begg's and Egger's tests were used for publication bias evaluation. A P-value of less than .05 was considered as statistically significant. The first search through databases resulted in 1382 papers. After removing duplicated papers and first-step screening based on title and abstract, 121 papers were assessed for eligibility. Finally, 23 articles were entered into the meta-analysis. PRISMA flow diagram for the study selection process is presented in Figure 1 . Among the 23 studies included in the meta-analysis, all were de- Results of quality assessment for studies entered into meta-analysis were fair. The findings of Begg's and Egger's tests were as follows for publica- The meta-analysis of event rates in peer-reviewed papers showed that 41% of COVID-19 patients were suffering from vitamin D deficiency (95% CI, 29%-55%), in 42% of patients, levels of vitamin D were lower than the normal range (95% CI, 24%-63%) and only 19% of patients had normal vitamin D levels (95% CI, 11%-32%) ( Figure 2 ). The The meta-analysis indicated that odds of getting infected with SARS-CoV-2 increase by 3.3 times in individuals with vitamin D deficiency (95% CI, 2.5-4.3) (Figure 4 ). The meta-analysis showed that the probability of developing severe stages of COVID-19 is 5.1 times higher in patients with vitamin D deficiency (95% CI, 2.6-10.3) ( Figure 5 ). The meta-analysis indicated no significant higher COVID-19 mortality related to vitamin-D-deficient patients (OR: 1.6, 95% CI, 0.5-4.4) ( Figure 6 ). Meta-analysis of available data on comorbidities frequency in COVID-19 patients was as follows: in non-severe cases, 13% cancer, 12% chronic kidney disease (CKD), 18% cardiovascular diseases (CVD), 21% diabetes, 29% hypertension (HTN), 12% obesity and 13% respiratory diseases ( Figure S1 ); in severe cases, 13% cancer, 34% CKD, 31% CVD, 35% diabetes, 64% HTN, 33% obesity and 17% respiratory diseases ( Figure S2 ); in overall, 8% cancer, 20% CKD, 26% CVD, 5% dementia, 15% depression/anxiety, 22% obesity, 26% diabetes, 49% HTN and 15% respiratory diseases ( Figure S3 ). Pooling available data regarding ethnicity distribution among COVID-19 patients resulted in 2% Afro-Caribbean, 13% Asian and 87% Caucasian ( Figure S4 ). The results for severe cases were as follows: 2% Asian, 68% Caucasian and 81% Hispanic ( Figure S5 ). Although comparing global statistics of COVID-19 outcomes is difficult, it is clear that the mortality rate is higher in several countries. It seems that among various factors such as age patients, 20 which have underestimated first, but the value was revealed after a while. According to available data entered into our meta-analysis, we could find that approximately 43% of the patients infected with SARS-CoV-2 were suffering from vitamin D deficiency, and this vitamin was insufficient in about 42% of them. We have also found that mean 25(OH)D levels were low (~20 ng/mL) in all COVID-19 patients. More importantly, our analysis showed that the chance of After months of investigation on COVID-19, several factors, such as male sex, older age, CVD, HTN, chronic lung disease, obesity and CKD, are proposed to be risk factors towards deteriorating COVID-19 patients' outcomes. [28] [29] [30] [31] Interestingly, one of the conditions that lead to most of the considered risk factors is vitamin D deficiency. Studies indicated that malignancies, diabetes, HTN and CVDs are significantly related to vitamin D deficiency. Also, studies reported the important role of vitamin D deficiency in older males. [32] [33] [34] Evidence shows that ageing, physical activity, obesity, seasonal variation, less vitamin D absorption, pregnancy, thyroid disorders, prolonged use of corticosteroids and ethnicity/race can substantially affect the circulating 25(OH)D levels. [35] [36] [37] [38] [39] [40] [41] Hence, although studies reported vitamin D deficiency as one of the critical risk factors in clinical outcomes of COVID-19 patients, it seems that it can also be in a strong relationship with basic underlying risk factors and diseases in such patients. In this case, our analyses indicated that HTN, CVDs, CKDs, diabetes, obesity and respiratory diseases were the most frequent comorbidities in COVID-19 patients. According to the facts mentioned above and our findings, it is plausible that both vitamin D deficiency and underlying diseases, which affect each other, may worsen the condition of these patients more than others. Vitamin D metabolism has been well studied throughout history. Numerous investigations indicate vitamin D's roles in reducing microbial infections through a physical barrier, natural immunity and adaptive immunity. Besides, according to the revealed association of SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2), this virus can substantially down-regulate the ACE2 expression, which seems to lead the COVID-19 patients to deterioration. [75] [76] [77] In contrast, vitamin D affects the renin-angiotensin system pathway and promotes the expression of ACE2. 78, 79 However, since the high expression of ACE2 can be a risk factor for the severity of the disease, 80 it is not yet clear enough to conclude how much vitamin D helps the condition. Hence, more evidence and trials are needed to design a treatment plan for three groups of mild, moderate and severe patients. It is worth noticing that the current meta-analysis includes the Eventually, to overcome the limitations and bias, the study's results should be confirmed by robustly large multicentre randomised clinical trials. The conditional evidence recommends that vitamin D might be a critical supportive agent for the immune system, mainly in cytokine response regulation against pathogens. In this systematic review and meta-analysis, we found that mean serum 25(OH)D level was low (~20 ng/mL) in all COVID-19 patients and most of them were suffering from vitamin D deficiency/insufficiency. Also, there is about three times higher chance of getting infected with SARS-CoV-2 among vitamin-D-deficient individuals and five times higher probability of developing the severe disease in such patients. Vitamin D deficiency showed no significant association with mortality rates in these population. The Caucasian was the dominant ethnic group, and the most frequent comorbidities in COVID-19 patients were HTN, CVDs, CKDs, diabetes, obesity and respiratory diseases, which might be affected by vitamin D deficiency directly or indirectly. However, further large clinical trials following comprehensive meta-analysis should be taken into account to achieve more reliable findings. We would like to express our appreciation to the Student Research The authors declare that they have no competing interests. Not applicable. Coronavirus Disease (COVID-2019) Situation Reports. WHO Modulation of the immune response to respiratory viruses by vitamin D Vitamin D modulation of innate immune responses to respiratory viral infections Evidence regarding vitamin D and risk of COVID-19 and its severity Vitamin D and the immune system Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebocontrolled trial The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses Panethnic differences in blood pressure in Europe: a systematic review and metaanalysis Appendix: Jadad scale for reporting randomized controlled trials. Evidence-based Obstetric Anesthesia Controversies in vitamin D: summary statement from an international conference Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 The interplay between vitamin D and viral infections Vitamin D deficiency in young children with severe acute lower respiratory infection Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis Serum vitamin D concentrations and associated severity of acute lower respiratory tract infections in Japanese hospitalized children Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data Vitamin D and respiratory tract infections: a systematic review and metaanalysis of randomized controlled trials Vitamin D for prevention of respiratory tract infections. WHO; e-Library of Evidence for Nutrition Actions (eLENA) the role of hydroxychloroquine in COVID-19: a systematic review and meta-analysis Considerations for obesity, vitamin D, and physical activity amid the COVID-19 pandemic The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality COVID-19 and vitamin D-is there a link and an opportunity for intervention? Vitamin D, covid-19 and children Vitamin D deficiency and the COVID-19 pandemic SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study Centers for Disease C, Prevention. People with certain medical conditions Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis Vitamin D deficiency in older men Vitamin D and the elderly Sex-Specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D The implication of vitamin D and autoimmunity: a comprehensive review Vitamin D deficiency: consequence or cause of obesity? The role of vitamin D in thyroid diseases Impact of isocaloric exchanges of carbohydrate for fat on postprandial glucose, insulin, triglycerides, and free fatty acid responses-a systematic review and meta-analysis Vitamin D deficiency in Europe: pandemic? Probability of vitamin D deficiency by body weight and race/ethnicity Ethnic aspects of vitamin D deficiency. Arquivos brasileiros de endocrinologia e metabologia COVID-19 and African Americans Are clinicians contributing to excess African American COVID-19 deaths? Unbeknownst to them, They may be The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities Is ethnicity linked to incidence or outcomes of covid-19? Vitamin D concentrations and COVID-19 infection in UK Biobank WHO report highlights Africa's health challenges Identifying key challenges facing healthcare systems in Africa and potential solutions The African regional health report 2014: The health of the people Vitamin D: in the evolution of human skin colour 25-Hydroxyvitamin D levels in African-American and Caucasian/ Hispanic subjects with cutaneous lupus erythematosus Vitamin D-binding protein and vitamin D status of black Americans and white Americans New aspects of vitamin D metabolism and action -addressing the skin as source and target Genetic predisposition models to COVID-19 infection The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic Free 25(OH)D and the Vitamin D paradox in African Americans Vitamin D deficiency An update on vitamin D and human immunity Vitamin D and the anti-viral state The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and echinacea in three main immune interactive clusters (physical barriers, innate and adaptive immunity) involved during an episode of common colds-practical advice on dosages and on the time to take these nutrients/botanicals in order to prevent or treat common colds Yes, vitamin D can be a magic bullet Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense Immunomodulatory effects of vitamin D on innate and adaptive immune responses to Streptococcus pneumoniae Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths 1, 25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes Decreased anti-inflammatory responses to vitamin D in neonatal neutrophils Complement as a target in COVID-19? Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis Vitamin D controls tumor growth and CD8+ T cell infiltration in breast cancer Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients Functional exhaustion of antiviral lymphocytes in COVID-19 patients Fighting COVID-19 exhausts T cells DAMP-driven metabolic adaptation ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach Angiotensin-converting enzyme 2 protects from severe acute lung failure Vitamin-D and COVID-19: do deficient risk a poorer outcome? Vitamin D supplementation alters the expression of genes associated with hypertension and did not induce DNA damage in rats Is the ACE2 overexpression a risk factor for COVID-19 infection Nutritional status of patients with COVID-19 Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection Vitamin D status and outcomes for hospitalised older patients with COVID-19 Association of vitamin D status and other clinical characteristics with COVID-19 test results Vitamin D deficiency and ARDS after SARS-CoV-2 infection Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19 Serum 25-hydroxyvitamin D levels and psychological distress symptoms in patients with affective disorders during the COVID-19 pandemic Interaction between age and vitamin D deficiency in severe COVID-19 infection Impact of serum 25(OH) vitamin D level on mortality in patients with COVID-19 in Turkey The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: a casecontrol study of hospitalized patients in Tehran, Iran Serum levels of vitamin C and vitamin D in a cohort of critically Ill COVID-19 patients of a North American community hospital intensive care unit in May 2020: a pilot study Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital Role of vitamin D in pathogenesis and severity of coronavirus disease 2019 (COVID-19) infection Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional multi-centre observational study Vitamin D deficiency is inversely associated with COVID-19 incidence and disease severity in chinese people Vitamin D deficiency and outcome of COVID-19 patients Vitamin D deficiency correlates with a reduced number of natural killer cells in intensive care unit (ICU) and non-ICU patients with COVID-19 pneumonia Does serum vitamin D level affect COVID-19 infection and its severity? A case-control study Serum 25 (OH) D level in patients with COVID-19 Additional Supporting Information may be found online in the Supporting Information section Not applicable.